Since the greatest benefit of these novel treatment regimens is most strikingly seen in patients with BRCA1/2‐mutant or HRD‐positive ovarian cancer, and less pronounced in wtBRCA1/2 and HRD‐negative ovarian cancers, there is a clinical need to identify high‐risk patients with wtBRCA1/2/HRD‐negative ovarian cancers. This evidence concerns the gene BRCA1 and ovarian carcinoma.